These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1006 related articles for article (PubMed ID: 29174294)

  • 1. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide hormone ghrelin enhances neuronal excitability by inhibition of Kv7/KCNQ channels.
    Shi L; Bian X; Qu Z; Ma Z; Zhou Y; Wang K; Jiang H; Xie J
    Nat Commun; 2013; 4():1435. PubMed ID: 23385580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
    Fletcher EJR; Moon LDF; Duty S
    BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons.
    Gui ZH; Liu J; Wang Y; Ali U; Wang T; Chen L
    Chin J Physiol; 2011 Apr; 54(2):96-104. PubMed ID: 21789890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.
    Hansen HH; Ebbesen C; Mathiesen C; Weikop P; Rønn LC; Waroux O; Scuvée-Moreau J; Seutin V; Mikkelsen JD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1006-19. PubMed ID: 16775195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered melatonin MT
    Kang NH; Carriere CH; Bahna SG; Niles LP
    Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Sleeman IJ; Boshoff EL; Duty S
    Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J; Sharma MK; Gengler S; Hölscher C
    Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
    Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
    Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease.
    Sarookhani MR; Haghdoost-Yazdi H; Sarbazi-Golezari A; Babayan-Tazehkand A; Rastgoo N
    Behav Pharmacol; 2018 Jun; 29(4):336-343. PubMed ID: 29239973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in SK channel expression in the basal ganglia after partial nigrostriatal dopamine lesions in rats: Functional consequences.
    Mourre C; Manrique C; Camon J; Aidi-Knani S; Deltheil T; Turle-Lorenzo N; Guiraudie-Capraz G; Amalric M
    Neuropharmacology; 2017 Feb; 113(Pt A):519-532. PubMed ID: 27825825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
    Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
    Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of magnesium transporter SLC41A1 in the striatum of 6-hydroxydopamine-induced parkinsonian rats.
    Lin L; Yan M; Wu B; Lin R; Zheng Z
    Brain Res Bull; 2018 Sep; 142():338-343. PubMed ID: 30172737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental change on dopaminergic neurons in striatum of Parkinson disease rats.
    Chen XY; Li J; Qi WQ; Shen SH
    Histol Histopathol; 2007 Oct; 22(10):1085-90. PubMed ID: 17616935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.